Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
The AAPS Journal|May 4, 2021
Bioanalysis in the Age of New Drug ModalitiesJing Shi, Xuesong Chen, Jianbo Diao, et al.
The American Journal of Surgical Pathology|June 13, 2023
Triple-negative Breast Carcinoma With Apocrine and Histiocytoid Features: A Clinicopathologic and Molecular Study of 18 CasesYihong Wang, Sean M Hacking, Zaibo Li, et al.
NPJ Precision Oncology|May 20, 2026
MYC contributes to targeted therapy resistance in lung cancers driven by MET exon 14-skipping alterationDaniel Lu, Sarah Okun, Tom Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 28, 2023
Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLCIgor Odintsov, Maisam Makarem, Mizuki Nishino, et al.
Biorxiv : the Preprint Server for Biology|November 26, 2025
<i>RRAS</i> and <i>RRAS2</i> mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236Alexander J Pfeil, Tom Zhang, Ryan Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2026
RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236Alexander J Pfeil, Tom Zhang, Ryan Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2024
HER2 Antibody-Drug Conjugates Are Active against Desmoplastic Small Round Cell TumorTom Zhang, Christopher A Febres-Aldana, Zebing Liu, et al.
Cancer Discovery|February 18, 2025
Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted TherapyChristopher A Febres-Aldana, Morana Vojnic, Igor Odintsov, et al.
Nature Cancer|September 24, 2023
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutationsIsao Miyazaki, Igor Odintsov, Keiji Ishida, et al.
Pageof 2